| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Blonder Tongue Laboratories, Inc. (NYSE:BDR) announced today that its Board of Directors has authorized a review of strategic alternatives for the Company aimed at enhancing stockholder value. Emerging Growth Equities, Ltd. has been engaged to serve as the exclusive financial advisor to the Board of Directors.
The Company does not intend to make any further statements regarding the process of reviewing strategic alternatives unless and until a definitive agreement has been reached or until the process has otherwise ended, unless required by applicable law. No assurance can be given as to whether, when or on what terms any possible transaction might occur.
Posted In: BDR
